Is levetiracetam (Keppra) and lacosamide (Vimpat) a good combination for epilepsy treatment?

Levetiracetam and Lacosamide: An Effective Combination for Epilepsy Treatment

The combination of levetiracetam (Keppra) and lacosamide (Vimpat) is an effective treatment option for epilepsy, particularly as an add-on therapy for patients whose seizures are not adequately controlled with monotherapy. This combination offers complementary mechanisms of action that can improve seizure control while maintaining a favorable safety profile compared to other antiepileptic drug combinations.

Efficacy of the Combination

Levetiracetam and lacosamide work through different mechanisms:

• Levetiracetam binds to synaptic vesicle protein 2A (SV2A)
• Lacosamide enhances slow inactivation of voltage-gated sodium channels

This mechanistic difference provides a rational basis for their combination:

• Research shows that adding lacosamide to levetiracetam background therapy can be effective for patients with focal epilepsy not adequately controlled on previous regimens 1.
• A study examining this specific combination demonstrated a high retention rate of 83.3% among patients who successfully transitioned from a sodium channel blocker to the levetiracetam/lacosamide combination 1.
• The combination therapy significantly enhances therapeutic effect and improves neural function in patients with refractory partial seizures 2.

Safety Profile and Psychiatric Considerations

The psychiatric side effect profile of this combination is particularly favorable:

• The incidence of psychiatric disorders is significantly lower (6.8%) with levetiracetam + lacosamide compared to levetiracetam + perampanel (44%) 3.
• This is an important consideration since levetiracetam alone is known to cause psychiatric side effects in some patients 4.

Guideline Support

Current guidelines support this combination approach:

• The EANO-ESMO clinical practice guidelines (2021) recognize lacosamide as an appropriate add-on treatment for patients whose seizure disorder is not controlled by monotherapy 4.
• Levetiracetam has become the drug of first choice at most neuro-oncology centers due to its efficacy and overall good tolerability 4.

Practical Considerations for Implementation

When initiating this combination:

1. Titration strategy:

   • Start with a flexible lacosamide up-titration (beginning at 100 mg/day)
   • Gradually increase to 200-600 mg/day over several weeks
   • Maintain stable levetiracetam dosing during this period

2. Monitoring requirements:

   • Watch for psychiatric symptoms, particularly within the first month of combination therapy
   • Monitor for dizziness, headache, and fatigue, which are the most common adverse events 1
   • Regular follow-up visits to assess seizure frequency and adverse effects

Potential Limitations and Caveats

• While this combination shows good efficacy, it may cause slight adverse effects on bone mineral density and bone metabolism in the short term 2.
• Driving performance may be affected during initial titration, but continued administration of either drug does not appear to result in clinically meaningful driving impairment 5.
• Individual patient factors such as age, pregnancy status, and comorbidities should be considered when selecting this combination.

The levetiracetam/lacosamide combination represents a rational polytherapy approach for epilepsy management, offering complementary mechanisms of action with a favorable safety profile compared to other combinations involving levetiracetam.